Equities

Abingdon Health PLC

ABDX:LSE

Abingdon Health PLC

Actions
Health CareMedical Equipment and Services
  • Price (GBX)11.20
  • Today's Change0.20 / 1.82%
  • Shares traded314.73k
  • 1 Year change-25.33%
  • Beta-0.5402
Data delayed at least 20 minutes, as of Jun 14 2024 16:35 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Abingdon Health plc provides lateral flow contract development and manufacturing (CDMO services) and related contract services to an international customer base. It offers its services to an international customer base across industry sectors, which include clinical, self-testing, animal health, plant health, and environmental testing. Its segments include Product sales, Contract manufacturing, Contract development, and Regulatory. Its regulatory services include technical file build, regulatory filing support, implementation of quality management systems and quality assurance. The Company’s CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Its Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to enable consumers to manage their own health and wellbeing.

  • Revenue in GBP (TTM)5.34m
  • Net income in GBP-2.24m
  • Incorporated2008
  • Employees82.00
  • Location
    Abingdon Health PLCYork Biotech Campus, Sand HuttonYORK YO41 1LZUnited KingdomGBR
  • Phone+44 190 440 6050
  • Fax+44 190 446 2122
  • Websitehttps://www.abingdonhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ImmuPharma PLC0.00-2.92m9.29m5.00--8.79-----0.0081-0.00810.000.00250.00----0.00-87.27-86.13-163.24-106.39-------8,634.98---8.610.00------23.26------
Bivictrix Therapeutics PLC0.00-2.55m10.11m10.00--2.86-----0.0351-0.03510.000.04290.00-------57.64---65.12--------------0.069-------1.92------
Destiny Pharma PLC0.00-5.66m10.51m19.00--1.14-----0.0624-0.06240.000.09650.00----0.00-60.33-54.32-67.28-59.97------------0.00------13.02--35.39--
Oncimmune Holdings PLC1.21m-3.19m10.64m56.00------8.76-0.04270.09390.0163-0.01720.17561.190.6917---46.21------63.34---263.10--1.01-0.68151.32--------------
Genflow Biosciences PLC0.00-1.63m10.84m5.00--12.49-----0.0056-0.00560.000.00250.00----0.00-88.30---105.34--------------0.00-------21.97------
Chill Brands Group PLC146.62k-3.64m10.89m2.00------74.24-0.0142-0.01420.0006-0.00240.03190.09920.363973,310.00-79.21-72.55-141.46-105.3553.05---2,485.30-1,625.460.6499-8.481.17---86.73-50.8923.50---35.95--
Synairgen plc0.00-9.99m11.66m30.00--0.7304-----0.0496-0.04960.000.07930.00----0.00-41.40-54.75-48.86-60.72-------83,247.62----0.00------63.74--0.00--
Proteome Sciences plc5.03m-2.44m12.43m35.00------2.47-0.0083-0.00830.017-0.01040.42093.893.04143,657.10-20.45-1.22----32.7654.53-48.59-2.200.2667-2.031.29---35.3710.52-284.38--126.22--
Genincode PLC2.16m-7.02m12.61m36.00--5.30--5.84-0.0732-0.07320.02250.01350.270321.883.3360,000.00-87.79---124.10--47.31---324.81--1.24--0.1883--51.05---26.21------
Provexis plc598.08k-496.59k14.14m2.00--14.10--23.65-0.0002-0.00020.00030.00040.67173.042.95299,040.00-55.78-48.82-41.86-33.6846.7286.14-83.03-97.641.96--0.00---8.5110.58-71.79------
Abingdon Health PLC5.34m-2.24m14.19m82.00--7.52--2.66-0.0184-0.01840.04390.01490.89787.674.7465,170.73-37.55-51.31-58.04-79.8557.3533.16-41.82-139.641.59--0.3572--42.68--83.77------
LungLife AI Inc36.27k-4.27m14.50m15.00--0.6986--399.68-0.1675-0.16750.00140.24480.0038--0.28312,418.13-44.11---50.09--100.00---11,767.39------0.0419--91.67--28.83------
Shield Therapeutics PLC13.09m-33.29m16.03m73.00--1.07--1.23-0.0458-0.04580.01810.01920.3473.651.31179,246.60-88.29-56.68-136.30-67.4430.7852.20-254.44-365.892.04-30.010.5739--137.951.9533.13---2.50--
OptiBiotix Health PLC689.10k-13.17m16.16m3.00--1.60--23.45-0.1489-0.14890.00780.10290.04262.281.25229,700.00-81.3517.83-83.4318.6649.3154.87-1,911.88190.543.24-0.0890.00---79.3519.05-58.686.2830.03--
Verici DX PLC798.77k-6.89m17.08m14.00--4.28--21.38-0.0404-0.04040.00470.01650.0932--1.5957,055.05-80.32---115.94--1.58---862.19------0.0438------23.43------
Hemogenyx Pharmaceuticals PLC0.00-6.69m19.12m17.00--5.94-----0.0061-0.00610.000.00240.00----0.00-101.47-82.19-112.85-95.97-----------28.030.5144-------68.14--36.68--
Data as of Jun 14 2024. Currency figures normalised to Abingdon Health PLC's reporting currency: UK Pound GBX

Institutional shareholders

9.75%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Asset Management Ltd.as of 08 Sep 202310.43m8.23%
Unicorn Asset Management Ltd.as of 31 May 20241.93m1.52%
Data from 31 May 2024 - 03 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.